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Blau Syndrome, the prototypic auto-inflammatory
granulomatous disease
Carine H Wouters1,2*, Anne Maes2, Kevin P Foley4, John Bertin4 and Carlos D Rose3

Abstract
Blau syndrome is a monogenic disease resulting from mutations in the pattern recognition receptor NOD2, and is
phenotypically characterized by the triad of granulomatous polyarthritis, dermatitis and uveitis. This paper reviews
briefly the classical clinical features of the disease, as well as more recently described extra-triad symptoms. From an
ongoing prospective multicenter study, we provide new data on the natural history of Blau syndrome, focusing on
functional status and visual outcome. We also present an update of the range of different NOD2 mutations found
in Blau syndrome as well as recent data on morphologic and immunohistochemical characteristics of the Blau
granuloma. Finally, emerging insights into pathogenic mechanisms including activation of NOD2 signal
transduction, and potential biomarkers of disease activity are discussed.
Keywords: Blau syndrome, Granulomatous diseases, NOD2, RIP2 kinase, Sarcoidosis, Uveitis

Introduction and nomenclature
In 1985, Blau syndrome (Blau) was described simultaneously by E Blau and D Jabs, as a familial granulomatous
inflammatory disease with an autosomal dominant inheritance pattern [1,2]. Once the causative mutations in
NOD2 were discovered [3] and later found to also be
present in patients with Early Onset Sarcoidosis - a sporadic disease with the same phenotype [4,5] - , it became
clear that Blau and Early Onset Sarcoidosis are the familial
and sporadic forms respectively, of the same disease. The
authors originally suggested a unifying name for these two
conditions, namely Pediatric Granulomatous Arthritis but
this term did not gain traction, partly because it concealed
the systemic and visceral manifestations of the disease [6].
Further, arthritis although highly prevalent in this condition, is not a universal feature. In this paper we will utilize
the term Blau syndrome to refer to both the sporadic and
familial forms of the disease, recognizing that the presence
or absence of a family history no longer has any relevance
in terms of disease classification; of course the presence of
an affected family member will be a valuable clinical feature for a diagnostician at the time of presentation.
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Blau syndrome classically presents in early childhood as
a triad of granulomatous dermatitis, arthritis and uveitis.
Although there are exceptions, skin rash is the first symptom to appear, usually in the first year of life. Between the
ages of 2–4 years, a boggy polyarthritis is observed. Finally, uveitis develops in 60–80% of patients at around
48 months of age [6]. The majority of data presented in
this review stem from two independent efforts. In 2005,
the Blau syndrome International Registry (also referred to
as the Pediatric Granulomatous Arthritis registry) was
instituted. Thanks to the collaborative efforts of physicians
taking care of Blau patients from around the world, genetic and clinical data based on retrospective review of
medical records have been collected. This registry received
support and is an integral part of the Eurofever project,
since Blau syndrome is considered to be one of the monogenic auto-inflammatory diseases. Second, since 2009, a
5-year prospective multicenter study to investigate the
natural history of the disease and its functional impact,
to promote biomarker discovery, and to gain a better
understanding of relevant pathogenic pathways, is being
conducted by the authors. Some of the preliminary findings from this latter international effort will be discussed
herein.
One of the most fascinating aspects of Blau syndrome is
the presence of non-caseating epithelioid and giant cell
granulomas in affected tissues. In fact, Blau syndrome is
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the only auto-inflammatory disease associated with a gain
of function mutation to show granulomatous inflammation. The morphologic characteristics of the “Blau granuloma” are similar to those found in sarcoidosis, which is
not associated with NOD2 mutations. Detailed morphological and immunohistochemistry studies on biopsy
tissue from Blau patients have provided some insights as
to the relevant pathogenic pathways involved in the disease process [7]; however there is still a significant knowledge gap concerning a link between the canonical NOD2
signaling pathway and granuloma formation.

Review
Classical clinical features

Blau arthritis manifests as a polyarticular “boggy” synovitis and tenosynovitis which constitutes a characteristic
phenotypical feature. Data from the Blau international
registry revealed polyarticular arthritis at presentation in
96% of patients with a “boggy”/exuberant aspect in 75%
[6]. Arthritis typically affects peripheral joints mainly
wrists, knees, ankles, and proximal interphalangeal (PIP)
joints of the hands. Other peripheral joints are less commonly affected and involvement of the axial skeleton
and the temporo-mandibular joint has not been described.
Tenosynovitis is equally a characteristic feature; tendon
sheaths appear enlarged on examination; most often the
extensor tendons of the wrist, the pes anserinus, peroneal
and flexor tibialis tendon sheaths are affected. Despite the
chronicity of exuberant arthritis, joint destruction is not
commonly reported, and range of motion is relatively well
preserved, especially in the larger joints. Conversely, the
PIP joints often develop a contracture relatively early in
the course of the disease and out of proportion to the
degree of synovitis. This deformity, originally described
as camptodactyly, may be the result of dysplastic changes,
distinct from the inflammation-associated joint contracture
as seen in polyarticular juvenile idiopathic arthritis (JIA)
[8]. Figures 1 and 2 show the characteristic appearance of
Blau arthritis. More detailed descriptions of the articular
phenotype are available in other publications [9-14].
The rash is usually the first to appear in Blau; however,
by the time the patients present to the rheumatologist all
one may find is either a residual pigmented, mildly scaly
rash on examination or simply a history of a “strange” rash
during infancy. Clinically the most frequent appearance is
that of an erythematous maculo-micropapular fine scaly
rash on the trunk and extremities in an infant. Intense
erythematous rashes have been described [15]; more commonly, the rash is misdiagnosed as atopic dermatitis, or
when desquamation is intense, as ichthyosis vulgaris. Blau
syndrome also has to be considered in the differential
diagnosis of neonatal dermatitis. In one report, a generalized erythematous micropapular dermatitis was described
in an infant of 1 week old at presentation with a skin

Figure 1 Exuberant ‘boggy’ synovitis of wrist in a child with
Blau syndrome.

biopsy showing non-caseating granulomas [15]. Later the
exanthema becomes tan-colored and may present a “dirty’
scaly appearance (Figure 3). The later stage of the rash
tends to last longer and may constitute a valuable diagnostic clue. When a skin biopsy is performed a non-caseating
granulomatous inflammatory infiltrate located in the dermis is characteristic (Figure 4). In the Blau international
registry, the skin has offered better diagnostic yield when
compared to synovium, with confirmatory histology in
more than 90% of the patients eventually diagnosed with
Blau [6].
Uveitis presents as an insidious granulomatous iridocyclitis with posterior uveitis in many patients, and a potential evolution into a severe panuveitis with multifocal
choroiditis. It is usually bilateral and associated with an
increased risk of visual morbidity. About 80% of patients
in both the retrospective international Blau registry
and the prospective Blau cohort study developed ocular disease with a median age at onset of 4.4 years
(unpublished data). Unlike the uveitis of JIA, which is

Figure 2 Tenosynovial swelling affecting tibialis posterior and
peroneal tendons in Blau syndrome.
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Figure 3 Tan colored “dirty” mildly scaly (late) rash.

almost always confined to the anterior uvea, involvement
of the entire uveal tract with panuveitis was found in 75%
of Blau patients in the prospective cohort study (unpublished data). Granulomatous uveitis may be suspected on
slit lamp examination by the presence of nodular peripheral keratic precipitates noted on the limbus [16]. The
synechiae tend to be focal, and there can be nodules in the
iris. Vitreous inflammation is common, and may remain
persistently active for years. Posterior involvement is
described as multifocal choroiditis.
Expanded manifestations

The first systematic study to show the importance of extratriad manifestations was published by Arostegui in 2007.

Figure 4 Granulomatous dermatitis. Inflammatory infiltrate of the
subpapilar dermis with typical multinucleated giant cells within a
non-caseating epithelioid cell Blau granuloma.
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Most notably fever and erythema nodosum were detected
quite commonly in this Spanish cohort [9]. As more
patients were recruited in the Blau international registry we
noticed expanded manifestations in about one third of
the patients [17]. Features included fever, sialadenitis,
lymphadenopathy, erythema nodosum, leukocytoclastic
vasculitis, transient neuropathies, granulomatous glomerular and interstitial nephritis, interstitial lung disease,
arterial hypertension, pericarditis, pulmonary embolism,
hepatic granulomas, splenic involvement and chronic
renal failure.
Some of the extra-triad manifestations are of particular
importance to be aware of when following Blau patients.
The association between large vessel vasculitis and Blau
syndrome was reported before the genetic mutation was
discovered [18-21]. Other investigators reported silent
aortitis in a patient with Blau syndrome [22]. We recently
described a case of Takayasu’s-like arteritis in a child from
India with a novel NOD2 mutation [23].
Also of note, two young patients from the international registry developed severe systemic hypertension;
although digital angiography could not demonstrate renovascular disease, the response to ACE inhibitors was
manifest [17]. A young patient with a typical triad phenotype without visceral manifestations for most of his life
succumbed to acute onset intractable pulmonary hypertension at the age of 22 years, within a few months from
the first symptoms of mild dyspnea (unpublished observation). Hence pulmonary and systemic hypertension may
be seen in the course of Blau syndrome, requiring careful
vigilance.
Cranial neuropathies, particularly facial palsy have also
been documented in Blau [2,21], but central nervous
system involvement has not been reported. A patient
with Blau syndrome and a new onset of a seizure disorder was recently published; yet the relationship with
the disease process was not clearly demonstrated [24].
Typical central nervous system manifestations seen in
adult sarcoidosis, namely meningeal and white matter
disease have not been described in Blau.
Interstitial lung disease, a major feature of adult
sarcoidosis, was originally not considered part of the
Blau phenotype. The first case with a documented
NOD2 mutation was reported by our group [25]. Pneumonitis in this child was characterized by ground glass
infiltrates in the upper lobes easily controllable with a
few weeks of corticosteroids, without sequelae and no
recurrence while on anti-TNF therapy. Interstitial lung
disease was observed in three additional patients of the
prospective Blau study.
Erythema nodosum has been mentioned frequently; in
fact it is the second most common cutaneous manifestation
of Blau syndrome. Also leukocytoclastic vasculitis has been
documented in a patient with Blau [26].
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Renal involvement has been described as an interstitial
nephritis in the context of Blau syndrome before the mutation was known [27]. The first case of acute glomerular
and interstitial nephritis with histological documentation
of granulomatous inflammation both in the interstitium
and the glomeruli was reported more recently [26].
Finally, involvement of the reticuloendotelial system is
not uncommon. We found generalized lymphadenopathies and splenomegaly in more than one-fifth of patients in the Blau prospective study. Hepatomegaly can
be seen, but liver enzymes and liver function are mostly
normal. We have reported hepatic granulomas on a liver
biopsy in a child with Blau syndrome without evidence
of hepatic injury neither histologically nor by laboratory
evaluation [28].

Disease course

To date all studies on Blau have been either short case
series or multicenter registries [6,9] based on retrospectively collected data. The natural history of Blau and its
functional consequences remain largely unknown. An ongoing prospective international study aiming at collecting
data on disease course, and evolution of articular, ocular
and visceral disease was established in 2009. At the time
of writing this review, baseline visit data on the first
31 recruited Blau patients with a median disease course
of 12.8 yrs were available (manuscript under review).
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At the time of evaluation, more than fifty percent of
Blau patients had articular deformities, with camptodactyly (flexion contracture at PIP joints) being most commonly observed. Radiographs of hands and wrist very
rarely showed erosions, however some morphological
changes of radial, ulnar and carpal bones were apparent
[8]. Functional capacity, assessed by CHAQ and HAQ,
showed normal function in more than one-third of patients, mild impairment in one-third and moderate/severe
in almost one-third. Almost half of Blau patients reported
a moderate to severe impact of the disease on their global
well-being, and moderate to severe pain [8].
The large majority of patients with uveitis had active
eye involvement after 15 yrs. More than one-third had
ocular complications (including band keratopathy, increased intraocular pressure, cataracts, optic atrophy,
macular edema and retinal detachment), and almost
two-thirds had visual loss [8]. Figure 5 depicts the distribution of visual outcome at baseline.
At present, there is no evidence for an effective treatment for all patients with Blau. In the prospective Blau cohort study, more than two-thirds of Blau patients received
medical therapy, often combining systemic steroids,
immunosuppressive and/or biologic drugs to control
both uveitis and arthritis. TNF-antagonists are the most
commonly used biological therapy and seemingly useful
in achieving partial control of articular disease. A few
investigators however have reported a dramatic response

Figure 5 Distribution of visual acuity in a cohort of 22 patients with Blau syndrome associated uveitis after an average follow up of
12.5 years. Visual acuity was converted into logMAR units by calculating the –Log of the visual acuity in decimal Snellen scale in meters.
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both clinically and biologically to IL-1 inhibition [9,29].
The observation of persistently active disease in a majority
of Blau patients in this study underlines the need for
development of effective targeted therapies.
The NOD2 genotypic spectrum

In the initial report in which NOD2 was identified as the
causative gene in Blau syndrome, three different single
base pair mutations were described in 4 families [3]. Two
of these families exhibited the same mutation, encoding
an amino acid substitution of arginine to tryptophan at
position 334 (R334Q), one family had an R334W, and
one other a L469F substitution. The following year,
Wang et al. published their study on the genetic analysis
of NOD2 coding regions based on 10 families with Blau
syndrome including members of the original family
published by E. Blau [21]. This paper mentioned a surprisingly low frequency of NOD2 mutations in patients
with Blau; 5 of the 10 families did not show any mutations, yet the description of the phenotypes was not very
detailed. A large series reported by investigators from
Japan identified NOD2 mutations in 90% of their cases
[30]. In the international Blau registry, all patients with
the classical clinical triad phenotype had a NOD2
mutation [6].
Over time the number of different NOD2 mutations
associated with Blau has expanded greatly [31-36]. An
update was published in 2011 by the authors [37], and
new Blau-associated NOD2 mutations are being cataloged regularly in the Infevers registry [38].
Most of the Blau mutations reported to date are at or
near the nucleotide-binding NOD/NACHT domain of the
NOD2 protein, yet they can also be found extending into
the C-terminal region characterized by a leucine-rich
repeat (LRR) structure. Figure 6 depicts the distribution of
NOD2 mutations found among 82 patients enrolled in the
international registry confirming that the majority of patients have either R334Q or R334W mutations, and most
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of them are within/near the NACHT domain. We found
one individual with a classical phenotype and a substitution at position 802, corresponding to the LRR region
(Figure 6). An E600A mutation was also found in affected
members of a three-generation family with isolated granulomatous uveitis, and also reported in an individual with
classical Blau [17].
It is unclear whether the type and/or location of the
NOD2 mutation has an effect on the clinical features. In a
study from Japan, an increased frequency and severity of
ocular involvement was reported in association with
R334W substitution [39], a finding we could not confirm
in neither the international Blau registry nor the current
prospective study.
Interestingly, although the penetrance of Blau-associated
NOD2 mutations is very high, we reported a family with an
E383K substitution, in which 2 members had the typical
Blau phenotype and 4 additional members (including one
adult) with the same substitutions, were asymptomatic [40].
Incomplete phenotypes are not uncommon; about
15-20% of patients with Blau syndrome do not develop
eye disease. In addition, we recently described a young girl
with a novel G464W substitution, who presented with
an atypical phenotype comprising mild oligoarthritis,
a Takayasu’s like large-vessel arteritis, but absence of rash
and no uveitis [23].
Blau granuloma morphology and immunohistochemistry

Granulomas are organized inflammatory infiltrates characterized by a core of macrophages, epithelioid cells,
multinucleated giant cells and a corona of lymphocytes
and a variable presence of fibroblasts. Blau is the only
auto-inflammatory disease with a gain-of-function mutation and granulomatous inflammation in affected tissues
and organs. Interestingly, granulomas also commonly occur
in the gastrointestinal tract in Crohn’s disease, and a subset
of Crohn’s patients carry polymorphisms in NOD2, which
are generally believed to confer loss of function [41].

Figure 6 Distribution of NOD 2 mutations in 82 patients of the International Blau registry (6).
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We have performed an in-depth morphological and
immunohistochemical study on granuloma-containing
biopsies from Blau patients as well as from patients with
Crohn’s disease and NOD2 polymorphisms. Our data
show that Blau granulomas display a distinct morphology
characterized by large polycyclic granulomas with dense
lymphocytic coronas, reflecting an exuberant inflammatory response, and in line with a gain-of-function mutation in NOD2. In contrast, biopsies from Crohn’s patients
show isolated granulomas with loose lymphocytic borders
and sclerosis of surrounding tissue, which are also seen in
immunodeficiency disorders, and therefore compatible
with loss-of-function variants of NOD2 [7].
In these studies, using immunohistochemistry, an abundant inflammatory cytokine expression was observed in
situ in Blau granulomas. A prominent expression of IFN-γ
was seen, which is in accordance with an important role
for Th1 lymphocytes in granulomatous inflammation, as
reported earlier in adult sarcoidosis [42]. In addition, we
found a very high expression of IL-6, TGF- β and IL-17 as
well as an increased expression of the IL-23 receptor on
granuloma cells (Figure 7) [7], compatible with activation of
the Th17 lymphocyte axis. A role for NOD2 in the induction of the Th17 axis has been reported by Van Beelen et al.
who showed that in vitro stimulation of human dendritic
cells with the NOD2-ligand muramyl dipeptide resulted in
promotion of IL-17 expression and Th17 differentiation
from memory T cells. Conversely, NOD2-defective dendritic cells from Crohn’s disease patients had marked
impairment in inducing Th17 polarization from memory
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T-cells [43]. Activation of Th-17 cells in Blau syndrome
granulomas would be compatible with a gain-of-function
mutations of NOD2 causing the disease. Of interest, a role
for both Th1 and Th17 cells in adult sarcoidosis has been
reported recently [42].
In Blau granulomas, we also have documented widespread extensive emperipolesis (cell-in-cell phenomenon)
of lymphocytes within multinucleated giant cells, which is
associated with multinucleated giant cell death, a finding
of interest in view of the recently reported role of NOD2
in autophagy (Figure 7) [7].
Blau syndrome new insights into pathogenesis

A full account of the biology of the NOD2 protein is beyond the scope of this article, and has been extensively
reviewed elsewhere [44,45]. Briefly, NOD2 is a member
of the NOD-like receptor (NLR) family of pattern recognition receptors, which are involved in inflammation and
innate immune defense against invading pathogens. NOD2
has a tripartite structure with two N-terminal CARD domains, one centrally located NOD/NACHT domain and a
C-terminal domain comprised of ten leucine-rich repeat
(LRR) motifs (Figure 6). The LRR domain binds the NOD2
ligand muramyl dipeptide (MDP), a degradation product of
ubiquitous bacterial cell wall peptidoglycan (Figure 6).
The classical pathway of NOD2 activation begins with
oligomerization of NOD2 after ligand-receptor engagement
(Figure 8). It has been postulated that in its unstimulated
state, NOD2 is autoinhibited via intramolecular interaction
between its LRR and CARD domains. Engagement of MDP

Figure 7 Morphological and immunohistochemical characteristics of Blau granulomas. Brown colour denotes positive cytokine staining.
A (top left). H & E staining showing prominent lymphocyte corona, emperipoletic lymphocytes, and multinucleated giant cell death with
fragmented cytoplasm and pycnotic nuclei. Using immunohistochmistry dense staining was observed for IFN-γ (B, top right, low magnification
showing several granulomas), IL-6 (C, bottom left, single granuloma showing predominant staining in corona) and IL-17 (D, bottom right, single
granuloma with giant cell in center showing strong Il-17 staining).
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Figure 8 Schematic representation of the NOD2 signaling pathway. Upon binding of its natural ligand (MDP), the NOD2 protein unfolds and
oligomerizes through the NACT domain. This is followed by recruitment of RIP2 kinase protein through CARD-CARD interactions and activation of
downstream transcriptional factors (NF-κB and MAP kinase) and secretion of inflammatory cytokines.

ligand leads to unfolding from this autoinhibited state and
oligomerization via the exposed NOD/NACHT domain.
This results in activation and further engagement of RIP2
kinase, its immediate downstream signaling partner via
interaction between the CARD domains of each protein.
Consequent activation of the key downstream signaling
molecules NF-κB and MAP kinase ultimately results in
production of inflammatory cytokines such as IL-1β, IL-6,
IL-8, TNF-α, and a variety of other cytokines, chemokines
and adhesion molecules. The physiological role of NOD2
has been expanding beyond being an innate line of defense
against intracellular bacterial infections and equally involves
a role in the defense against Toxoplasma [46], as a viral
pattern recognition receptor [47], and in the induction of
the autophagy process initiated by intracellular bacteria eg
Shigella flexneri [48].
The hypothesis that NOD2 mutations in Blau syndrome
act in a gain of function manner was initially suggested by
the autosomal dominant inheritance pattern of the disease
[3]. Subsequently, studies by two groups demonstrated
that over-expression of NOD2 carrying Blau mutations in
transfected cells resulted in the hyper-activation of an
NF-κB responsive reporter gene, whereas expression of
NOD2 carrying loss of function Crohn’s disease mutations failed to activate the same reporter [30,49]. These
results are consistent with the observation that Blau
NOD2 mutations occur in amino acid positions homologous to known gain of function mutations occurring
in the related pattern recognitions receptor NLRP3
which lead to spontaneous IL-1β production in the autoinflammatory Cryopyrin-associated periodic syndromes
(CAPS) [50].

Based on these studies, NF-κB activation and excess
inflammatory cytokine production as a consequence of
dominant gain of function mutations in NOD2 has become
a widely accept concept in the field. However, we and other
groups have observed that, in contrast to NLRP3-mutated
CAPS, peripheral blood cells from Blau patients do not
spontaneously produces inflammatory cytokines, and are in
fact resistant to stimulation by the NOD2 ligand MDP
[51,52]. Although this may appear to be at odds with a gain
of function model, it should be remembered that these peripheral cell populations may not reflect the activation state
of immune cells present within granulomas in diseased
tissue, where, as described above, we have seen evidence of
constitutive inflammation. Indeed, we have also detected
increased expression of S100A12 in Blau patient plasma,
which is a marker of neutrophil-mediated inflammation
[52]. Reconciling all these observations will obviously
require further work, particularly to understand the relationship between Blau gain of function mutations and
the mechanism of granuloma formation.

Conclusion
The clinical spectrum of NOD2-associated granulomatous inflammatory diseases continues to expand. NOD2
mutations associated with Blau syndrome extend beyond
the NACHT domain. The rarity of Blau syndrome has
made it challenging to fully characterize the disease.
However, the recent creation of an international registry
and the ongoing natural history study are providing
novel insights into the symptomology and etiology of this
fascinating genetic disorder.
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With more data available on the natural history of
Blau syndrome, the need for more effective therapies in
a substantial subset of patients is clear. Increased knowledge on NOD2 signaling and function remains essential
to advance our understanding of NOD2-hyperactivation
diseases.
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